###### Key questions

What is already known about this subject?
=========================================

-   There is no randomised controlled trial to support the use of mechanical circulatory support (MCS) in patients with acute myocardial infarction and cardiogenic shock. Little is known about the patient population receiving MCS in recent years. Observational studies show conflicting results but generally support implementation of MCS before revascularisation.

What does this study add?
=========================

-   The intra-aortic balloon pump (IABP) was replaced by Impella CP and, to a lesser extent, venoarterial membrane oxygenation following the neutral IABP-SHOCK II trial. Fewer patients received MCS after IABP-SHOCK II, and patients receiving MCS in recent years had more compromised haemodynamics at the time of shock compared with earlier years. When taking the timing of shock into consideration, not only prepercutaneous coronary intervention (PCI) implementation but also immediate post-PCI implementation of Impella CP was associated with improved outcome compared with a matched control group.

How might this impact on clinical practice?
===========================================

-   This study does not support general use of MCS, but if MCS is required, this observational study supports early use of Impella CP defined as pre-PCI, or immediately after PCI if shock develops during the procedure.

Introduction {#s1}
============

Cardiogenic shock remains a leading cause of death following acute myocardial infarction with sustained 30-day mortality of approximately 50% for nearly two decades.[@R1] Use of mechanical circulatory support (MCS) is widely debated with no substantial evidence supporting its use in patients with acute myocardial infarction and cardiogenic shock (AMICS). To date, the Intra-aortic Balloon Pump (IABP)-SHOCK II trial is the only adequately powered randomised controlled trial assessing the use of MCS in AMICS, and the trial failed to show any prognostic benefit with the use of IABP.[@R3] Contemporary studies on temporal trends in use of MCS in AMICS are limited but generally show a shift in choice of the device with a decrease in the use of IABP and an increase in the use of other devices, namely, venoarterial extracorporeal membrane oxygenation (VA-ECMO) and transvalvular microaxial flow pumps.[@R4] In a recent retrospective study, general use of Impella was not associated with improved survival compared with the IABP.[@R6] However, the percutaneous assist devices pooled in the analyses have differing support capabilities and mode of action, and there is increasing evidence of a possible timing issue favouring early application of MCS.[@R7] Therefore, we sought to investigate the use of MCS in AMICS and assessed the temporal trends in the choice of the device and the patient characteristics of those receiving MCS between 2010 and 2017. Further, we assessed the survival benefit of early application of IABP or Impella CP compared with a matched control group.

Methods {#s2}
=======

Study population {#s2-1}
----------------

All patients fulfilling the criteria for AMICS in the cardiac catheterisation laboratory undergoing early percutaneous coronary intervention (PCI) (within 24 hours of symptom onset) from 2010 to 2017 were identified in the RETROSHOCK registry ([figure 1](#F1){ref-type="fig"}). RETROSHOCK is a retrospective registry including all consecutive patients with an individually validated diagnosis of AMICS, admitted to two tertiary cardiac centres that provide AMICS care for two-thirds of the Danish population.[@R1] AMICS was defined as persistent hypotension (systolic blood pressure of ≤90 mm Hg for \>30 min or use of vasoactive drugs), end-organ hypoperfusion (altered mental status, cold/clammy skin, oliguria or arterial lactate ≥2.5 mmol/L) and reduced cardiac function, caused by an acute myocardial infarction.

![Consort diagram of patient selection. Dotted line indicates the cut-off between the trend study and the matching study. AMICS, acute myocardial infarction and cardiogenic shock; CCL, cardiac catheterisation laboratory; eGFR, estimated glomerular filtration rate; IABP, intra-aortic balloon pump; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention.](openhrt-2019-001214f01){#F1}

Intervention and data collection {#s2-2}
--------------------------------

The intervention of interest was the use of short-term MCS and the device type (IABP, VA-ECMO, Impella V.2.5, Impella CP, Impella RP and Impella V.5.0) from 2010 to 2017. Patient characteristics were obtained at the time of shock (ie, in the cardiac catheterisation laboratory). Patients were stratified as those who received MCS versus those who did not (MCS vs no MCS), in addition to the time period (2010--2012 vs 2013--2017). Mean arterial pressure was calculated as diastolic blood pressure+0.33×pulse pressure. Estimated glomerular filtration rate (eGFR) was calculated based on age, gender and creatinine on arrival according to the Chronic Kidney Disease Epidemiology Collaboration equation.[@R13] Early MCS application was defined as the initiation of IABP/Impella CP before PCI in patients with shock prior to the procedure or before leaving the cardiac catheterisation laboratory in patients developing shock during the procedure. Timing of shock was determined as pre-PCI versus during PCI based on blood pressure, if not specified in the medical record. Additional MCS was defined as the use of more than one device. In the matched study, MCS escalation was defined as the transition to a more powerful device (ie, from no device to any MCS, IABP to any other MCS, Impella CP to VA-ECMO and Impella CP to Impella V.5.0). Patient delay was defined as the time from symptom onset to first medical contact. System delay was defined as the time from first medical contact to insertion of the guiding catheter.

Study endpoints {#s2-3}
---------------

The primary endpoint of this study was 30-day all-cause mortality in the intervention group and the matched control group. Secondary endpoints were the mode of in-hospital death (cardiac, anoxic brain damage or multiorgan failure) for the matched cohort and 30-day mortality for the entire cohort.

Propensity matching {#s2-4}
-------------------

Use of MCS was considered equal to initiating intensive care treatment, along with intubation and vasoactive drug infusion. Patients who died in the catheterisation laboratory before receiving any form of intensive care treatment were considered not to be potential candidates for MCS and therefore were excluded from the propensity matched analysis ([figure 1](#F1){ref-type="fig"}). Among the patients from 2010 to 2012, those receiving an early IABP were matched 1:1 to their nearest neighbour according to a propensity score. Likewise, among the patients from 2013 to 2017, those receiving an early Impella CP were matched 1:1 to their nearest neighbour according to a propensity score ([figure 1](#F1){ref-type="fig"}). The following baseline characteristics were used for calculating the propensity score as they have been identified as significant risk factors for death in AMICS: age (5-year increments), left ventricular ejection fraction (LVEF, increments of 5%), arterial lactate at the time of shock (≤2.0, 2.1--4.0, 4.1--6.0, 6.1--8.0, 8.1--10.0, 10.1--12.0 and \>12.0 mmol/L), eGFR (grouped as \<30, 30--44, 45--59, 60--89 and ≥90 mL/min/1.73 m^2^) and resuscitation for cardiac arrest before arrival in the cardiac catheterisation laboratory. We did not identify any residual confounding of age, eGFR or lactate as continuous variables within each respective stratum. Patients randomised to Impella CP as part of the ongoing DanGer Shock trial (NCT01633502) were excluded from the matched study ([figure 1](#F1){ref-type="fig"}).[@R14]

Statistics {#s2-5}
----------

Patient characteristics among those receiving MCS and those not receiving MCS were compared both within the same period and across different periods (MCS 2010--2012 vs MCS 2013--2017, no MCS 2010--2012 vs no MCS 2013--2017, MCS 2010--2012 vs no MCS 2010--2012 and MCS 2013--2017 vs no MCS 2013--2017). Student's t-test was used to compare Gaussian data reported as mean (SD); Wilcoxon rank-sum test was used to compare non-Gaussian data reported as median (Q1, Q3), and χ^2^ test (Fisher's exact test for sparse data) was used to compare proportions reported as number (percentage). Thirty-day mortality was estimated using the Kaplan-Meier method, and differences between groups were compared using the log-rank test. All statistical analyses were performed using STATA software V.14.2.

Results {#s3}
=======

A total of 903 patients presenting to the cardiac catheterisation laboratory with AMICS undergoing early PCI between 2010 and 2017 were identified in the registry ([figure 1](#F1){ref-type="fig"}). The use of MCS decreased from 50% in 2010 to 25% in 2017 ([figure 2](#F2){ref-type="fig"}). There was a major shift in the choice of MCS since 2012 with a substantial decrease in the application of IABP and a concomitant increase in the application of Impella CP ([figure 2](#F2){ref-type="fig"}). Given the marked change in the choice of device use over time, we compared patients receiving MCS before 2012 with those receiving MCS after 2012. Patients receiving MCS after 2012 were younger and had more compromised haemodynamics at the time of shock compared with patients receiving MCS before 2012 ([table 1](#T1){ref-type="table"} and [figure 3](#F3){ref-type="fig"}). Among patients not receiving MCS, more comorbidity and slightly more compromised haemodynamics were observed in those treated after 2012 compared with those treated before 2012. Otherwise, patient characteristics were balanced across the two eras ([table 1](#T1){ref-type="table"}). Patients not receiving MCS had nearly identical 30-day mortality (48%, p=0.95) across eras, but the need for transfusion was more frequent in the period before 2012.

![Temporal trends in the use of MCS from 2010 to 2017 with different Impella devices delineated. AMICS, acute myocardial infarction and cardiogenic shock; IABP: intra-aortic balloon pump; MCS, mechanical circulatory support; VA-ECMO: venoarterial extracorporeal membrane oxygenation.](openhrt-2019-001214f02){#F2}

![Box plot for age, systemic systolic blood pressure, arterial lactate and LVEF in patients receiving MCS versus not receiving MCS in the pre-IABP-SHOCK II (2010--2012) and post-IABP-SHOCK II period (2013--2017). IABP, intra-aortic balloon pump; LVEF, Left ventricular ejection fraction; MCS, mechanical circulatory support.](openhrt-2019-001214f03){#F3}

###### 

Baseline characteristics, in-hospital treatment and outcome of all patients with acute myocardial infarction and cardiogenic shock undergoing early percutaneous coronary intervention in southeastern Denmark, 2010--2017

                                           Missing data   MCS       No MCS            MCS versus no MCS                                                                   
  ---------------------------------------- -------------- --------- ----------------- ------------------- --------- ---------------- ---------------- --------- --------- ---------
  Number of patients                       279            624       133               146                           174              450                                  
  Age (years), mean (SD)                   0              0         66.0 (10.8)       61.4 (12.5)         0.001     65.7 (12.5)      66.8 (11.7)      0.32      0.84      \<0.001
  Male sex, n (%)                          0              0         109 (82.0)        127 (87.0)          0.25      130 (74.7)       332 (74.0)       0.84      0.13      0.001
  BMI (kg/m^2^), mean (SD)                 95/279         177/624   26.2 (4.0)        27.1 (4.4)          0.16      26.3 (4.2)       26.1 (4.5)       0.72      0.90      0.05
  IHD, n (%)                               10/279         27/624    36 (27.5)         35 (25.4)           0.69      26 (16.3)        118 (27.0)       0.007     0.02      0.70
  Previous MI, n (%)                       10/279         25/624    17 (13.0)         18 (13.0)           0.99      11 (6.9)         70 (16.0)        0.004     0.08      0.41
  Hypertension, n (%)                      12/279         35/624    60 (46.2)         57 (41.6)           0.45      67 (42.1)        219 (50.9)       0.06      0.49      0.06
  Dyslipidaemia, n (%)                     13/279         39/624    36 (27.9)         39 (28.5)           0.92      46 (29.3)        143 (33.4)       0.35      0.80      0.28
  PAD, n (%)                               13/279         34/624    6 (4.6)           6 (4.4)             0.94      9 (5.6)          37 (8.6)         0.23      0.70      0.11
  DM, n (%)                                13/279         34/624    21 (16.2)         19 (14.0)           0.62      23 (14.4)        70 (16.3)        0.57      0.68      0.52
  Previous stroke, n (%)                   13/279         34/624    9 (7.0)           6 (4.4)             0.37      5 (3.1)          34 (7.9)         0.04      0.17      0.17
  COPD, n (%)                              13/279         36/624    8 (6.2)           10 (7.3)            0.72      15 (9.4)         57 (13.3)        0.19      0.32      0.06
  Cardiac arrest, n (%)                    0              0         49 (36.8)         68 (46.6)           0.10      116 (66.7)       278 (61.8)       0.26      \<0.001   0.001
  STEMI                                    0              0         120 (90.2)        98 (67.1)           \<0.001   149 (85.6)       310 (68.9)       \<0.001   0.23      0.69
  Haemodynamics at the time of shock                                                                                                                                      
   Vasoactive drugs, n (%)                 4/279          6/624     40 (30.1)         72 (51.4)           \<0.001   75 (43.6)        168 (37.7)       0.18      0.02      0.004
   MAP, mean (SD), mm Hg                   18/279         26/624    62 (11)           58 (16)             0.02      65 (11)          62 (11)          0.002     0.02      0.002
   Heart rate (beats/min), mean (SD)       41/279         53/264    90 (25)           89 (31)             0.94      82 (23)          82 (23)          0.98      0.02      0.005
   LVEF (%), median (Q1, Q3)               15/279         34/624    30 (20, 35)       20 (10, 30)         \<0.001   35 (25, 45)      35 (20, 40)      0.10      \<0.001   \<0.001
   Lactate (mmol/L), median (Q1, Q3)       32/279         98/624    4.5 (2.7, 11.0)   8.3 (3.9, 12.6)     0.003     6.1 (3.1, 9.9)   5.7 (3.0, 8.7)   0.46      0.81      \<0.001
  In-hospital management and outcome                                                                                                                                      
   IABP first device, n (%)                0              0         107 (80.4)        9 (6.2)             \<0.001   --               --               --                  
   Impella CP first device                 0              0         9 (6.8)           107 (73.3)          \<0.001   --               --               --                  
   VA-ECMO first device                    0              0         0                 25 (17.1)           \<0.001   --               --               --                  
   Additional MCS, n (%)                   0              0         7 (5.3)           25 (17.1)           0.002     --               --               --                  
   Mechanical ventilation, n (%)           8/279          43/624    91 (71.1)         133 (93.0)          \<0.001   145 (89.5)       376 (89.7)       0.94      \<0.001   0.25
   Vasoactive drug use, overall, n (%)     0              0         116 (87.2)        139 (95.2)          0.02      149 (85.6)       386 (85.8)       0.96      0.69      0.002
   Dialysis, n (%)                         15/279         68/264    39 (31.2)         76 (54.7)           \<0.001   19 (12.2)        50 (12.5)        0.92      \<0.001   \<0.001
   Bleeding requiring transfusion, n (%)   4/279          2/624     41 (31.5)         85 (58.6)           \<0.001   32 (18.6)        48 (10.7)        0.008     0.009     \<0.001
   Limb ischaemia, n (%)                   5/279          3/624     5 (3.8)           19 (13.2)           0.009     3 (1.7)          5 (1.1)          0.39      0.30      \<0.001
   30-day mortality, n (%)                 0              0         49 (36.8)         78 (53.4)           0.007     84 (48.3)        218 (48.4)       0.95      0.05      0.35

BMI, body mass index; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; IABP, intra-aortic balloon pump; IHD, ischaemic heart disease; LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; MCS, mechanical circulatory support; MI, myocardial infarction; PAD, peripheral arterial disease; STEMI, ST elevation myocardial infarction; VA-ECMO, venoarterial extracorporeal membrane oxygenation.

We identified 40 patients receiving early IABP and 40 patients receiving early Impella CP. As all patients receiving early IABP/Impella CP survived to intensive care treatment, the matched controls were also limited to patients receiving intensive care. Values of matching covariates and other patient characteristics can be found in [table 2](#T2){ref-type="table"}. The Impella CP group had significantly lower 30-day mortality compared with the matched control group, corresponding to an average number needed to treat of 2.7 (30-day mortality 40.0% with early-Impella CP vs 77.5% with control, p\<0.001; [table 2](#T2){ref-type="table"} and [figure 4](#F4){ref-type="fig"}). The improved outcome in the early Impella CP group was mainly driven by fewer in-hospital cardiac deaths. Although there were numerically fewer deaths in the early IABP group compared with the matched control group, no statistically significant difference was observed (30-day mortality 27.5% with early IABP vs 37.5% with control, p=0.35). Following exclusion of patients developing shock during the procedure, 30-day mortality was for early Impella CP versus control: 40.9% vs 79.4%, p=0.005, and for early-IABP versus control: 36.0% vs 41.2%, p=0.61.

![Kaplan-Meier curves of 30-day mortality with early-Impella CP versus propensity score-matched controls and early-IABP versus propensity score-matched controls. Propensity score was calculated based on age, left ventricular ejection fraction, lactate levels, estimated glomerular filtration rate and cardiac arrest before arrival to the cardiac catheterisation laboratory. IABP: intra-aortic balloon pump.](openhrt-2019-001214f04){#F4}

###### 

Baseline characteristics, in-hospital treatment and outcome for the matched cohort

                                         Early IABP versus control   Early Impella CP versus control                                                 
  -------------------------------------- --------------------------- --------------------------------- --------- ----------------- ----------------- ---------
  Number of patients                     40                          40                                          40                40                
  Age (years), mean (SD)                 68.8 (11.1)                 69.1 (9.9)                        0.90      64.5 (10.1)       65.9 (13.3)       0.60
  Male sex, n (%)                        33 (82.5)                   28 (70.0)                         0.19      34 (85.5)         29 (72.5)         0.17
  BMI (kg/m^2^), mean (SD)               25.5 (3.7)                  26.6 (4.0)                        0.28      27.3              24.9              0.01
  IHD, n (%)                             11 (27.5)                   8 (20.5)                          0.47      14 (36.8)         17 (43.6)         0.55
  Previous MI, n (%)                     3 (7.5)                     4 (10.3)                          0.71      8 (21.1)          8 (20.0)          0.91
  Hypertension, n (%)                    25 (64.1)                   15 (39.5)                         0.03      22 (59.5)         23 (59.0)         0.97
  Dyslipidaemia, n (%)                   11 (28.2)                   9 (23.7)                          0.65      15 (40.5)         16 (41.0)         0.97
  PAD, n (%)                             1 (2.5)                     2 (5.1)                           0.61      2 (5.4)           6 (15.8)          0.26
  DM, n (%)                              9 (22.5)                    6 (15.4)                          0.42      7 (18.9)          4 (10.5)          0.35
  Previous stroke, n (%)                 4 (10.3)                    2 (5.1)                           0.68      1 (2.7)           1 (2.6)           1.00
  COPD, n (%)                            1 (2.6)                     3 (7.7)                           0.62      0 (0.0)           2 (5.3)           0.49
  Cardiac arrest, n (%)                  9 (22.5)                    10 (25.0)                         0.79      16 (40.0)         15 (37.5)         0.82
   Time to ROSC (min), median (Q1, Q3)   25 (18, 25)                 27 (17, 33)                       0.71      23 (15, 75)       27.5 (15, 70)     0.61
  STEMI, n (%)                           36 (90.0)                   38 (95.0)                         0.40      27 (67.5)         24 (60.0)         0.49
  Patient delay (min), median (Q1, Q3)   75 (20, 256)                108 (24, 205)                     0.91      34 (2, 229)       46 (14, 219)      0.46
  System delay (min), median (Q1, Q3)    149 (115, 194)              164 (120, 245)                    0.41      140 (105, 175)    142 (100, 250)    0.75
  Haemodynamics at the time of shock                                                                                                                 
   Shock before PCI procedure, n (%)     25 (62.5)                   34 (85.0)                         0.02      22 (55.0)         34 (85.0)         0.003
   Vasoactive drugs, n (%)               27 (67.5)                   27 (67.5)                         1.00      22 (55.0)         18 (45.0)         0.50
   MAP (mm Hg), mean (SD)                61 (11)                     64 (9)                            0.20      57 (16)           56 (21)           0.85
   Heart rate (beats/min), mean (SD)     94 (24)                     86 (22)                           0.15      95 (32)           77 (33)           0.02
   LVEF (%), median (Q1, Q3)             27.5 (20, 40)               30 (22.5, 37.5)                   0.76      15 (10, 25)       15 (10, 25)       0.77
   Lactate (mmol/L), median (Q1, Q3)     3.5 (1.8, 5.7)              3.2 (2.0, 5.9)                    0.92      8.5 (4.5, 11.7)   8.3 (3.7, 13.4)   0.72
  eGFR (mL/min/1.73 m^2^), mean (SD)     62 (24)                     60 (21)                           0.67      63 (21)           60 (19)           0.61
  In-hospital management and outcome                                                                                                                 
   30-day mortality, n (%)               11 (27.5)                   15 (37.5)                         0.32      16 (40.0)         31 (77.5)         \<0.001
   Cause of in-hospital death, n (%)                                                                                                                 
   Cardiac                               8 (20.0)                    7 (17.5)                          0.78      7 (17.5)          18 (45.0)         0.008
   Multiorgan failure                    1 (2.5)                     3 (7.5)                           1.00      6 (15.0)          5 (12.5)          1.00
   Anoxic brain injury                   1 (2.5)                     2 (5.0)                           1.00      2 (5.0)           3 (7.5)           1.00
   Other, n (%)                          1 (2.5)                     2 (5.0)                           1.00      1 (2.5)           2 (5.0)           1.00
   Mechanical ventilation, n (%)         24 (60.0)                   27 (67.5)                         0.49      36 (90.0)         35 (87.5)         1.00
   Vasoactive drug use overall, n (%)    36 (90.0)                   40 (100)                          0.12      39 (97.5)         39 (97.5)         1.00
   Escalating MCS, n (%)                 2 (5.0)                     19 (47.5)                         \<0.001   5 (12.5)          12 (30.0)         0.10
   Use of VA-ECMO                        0 (0.0)                     0 (0.0)                           1.00      4 (10.0)          7 (17.5)          0.35
   Renal replacement therapy for AKI     8 (20.5)                    8 (21.0)                          0.95      19 (48.7)         11 (28.2)         0.10
   Limb ischaemia                        1 (2.6)                     1 (2.5)                           1.00      4 (10.0)          3 (7.5)           1.00

AKI, acute kidney injury; BMI, body mass index; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; IABP, intra-aortic balloon pump; IHD, ischaemic heart disease; LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; MCS, mechanical circulatory support; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; ROSC, return of spontaneous circulation; STEMI, ST elevation myocardial infarction; VA-ECMO, venoarterial extracorporeal membrane oxygenation.

Discussion {#s4}
==========

The current study demonstrates major changes in the use of short-term MCS over the last decade. Patients receiving MCS in recent years were younger and had more profound cardiogenic shock compared with patients receiving MCS in previous years. Interestingly, the choice of MCS device changed drastically from IABP to mostly Impella CP after the IABP-SHOCK II trial in 2012. Early application of Impella CP was associated with lower 30-day mortality compared with the matched controls, a trend that was not be observed among patients with early application of IABP.

Previous studies from Europe and the USA have demonstrated similar temporal trends regarding the choice of MCS system with decreasing use of IABP and increasing use of VA-ECMO, axial pump-related devices and Tandem Heart, but not to the same degree as observed in the present study.[@R4] The abandonment of IABP coincides with the published results of the IABP-SHOCK II trial, and a similar change in practice has been reported from a single-centre in Berlin.[@R17] The present study is the first study to delineate between the Impella family of devices and to highlight the increased application of Impella CP for AMICS in recent years. It should be noted that Impella V.2.5 was used in the early years; however, its use decreased concomitant with the abandonment of IABP following the introduction of Impella CP. Also, the initiation of the randomised DanGer Shock trial (NCT01633502) involving the Impella CP in 2013 and patient recruitment at the two participating institutions likely led to increased awareness of Impella CP.[@R14] In addition, clinicians might have favoured the use of Impella CP over Impella V.2.5 given the increased blood flow by the Impella CP. Studies reporting on contemporary trends on patient populations receiving MCS is scarce, and this study shows that patients receiving MCS were younger and more haemodynamically compromised in recent years (2013--2017) compared with earlier years (2010--2012). MCS was applied in \~25% of cases in the post-IABP-SHOCK II era compared with \~50% in the pre-IABP-SHOCK II era, and was probably restricted to patients with more profound shock, explaining the more compromised haemodynamics of patients receiving MCS in recent years. This concept is further supported by the observed increase in mechanical ventilation, vasoactive drugs, dialysis and higher 30-day mortality in the MCS group from the post-IABP-SHOCK II era versus pre-IABP-SHOCK II era. Given the striking differences in the patient characteristics of those receiving MCS before and after 2012, we exclusively compared the treatment effects of early IABP/Impella CP in the two separate time eras.

In agreement with the IABP-SHOCK II trial, early application of IABP compared with the matched control group was not associated with improved outcome in this study.[@R3] Early application of Impella CP was associated with improved 30-day mortality corresponding to an average number needed to treat of three to avoid one fatality, assuming that the intervention drove the difference. This contrasts with the recent IMPRESS (MPella versus IABP Reduces mortality in STEMI patients treated with primary PCI in Severe cardiogenic SHOCK) randomised trial of 48 patients, which did not find an overall survival benefit of Impella CP compared with IABP.[@R10] In the trial, 91.7% of patients had cardiac arrest before randomisation and might represent an entirely different clinical entity compared with the mixed cohort of patients with AMICS. The trial did, however, report an absolute risk reduction of 28% in 30-day mortality when MCS was applied pre-PCI, although the numbers were small and difference did not reach statistical significance.[@R10] A recent single-centre observational study found a non-significant absolute 15% lower 30-day mortality among 62 patients receiving an Impella compared with 54 patients receiving an IABP, despite the fact that patients receiving Impella had more often received out-of-hospital cardiopulmonary resuscitation, had lower LVEF and had higher lactate levels at device implementation.[@R17] A recent multicentre observational study found no survival benefit with general use of Impella V.2.5/CP compared with matched patients from the IABP-SHOCK II trial cohort, but did report a non-significant absolute 10.6% lower 30-day mortality for Impella in the pre-PCI subgroup analysis.[@R6] Other observational studies have compared the effect of Impella application pre-PCI versus post-PCI, and the results favour pre-PCI Impella.[@R7] These studies may suffer from confounding by indication, as patients in whom PCI fails to stabilise haemodynamics and receive Impella post-PCI may have a worse outcome compared with those receiving Impella pre-PCI. Experimental animal studies have demonstrated that deploying an unloading MCS system prior to reperfusion has been demonstrated to reduce infarct size in various species, and that a strategy of Impella CP and norepinephrine improved end-organ perfusion without increasing myocardial workload in a large porcine model of profound cardiogenic shock.[@R18] In the present study, the improved survival effect of early Impella CP was primarily driven by fewer in-hospital cardiac deaths, supporting the association of improved outcome with early left ventricular unloading. However, no definite conclusions can be drawn from this observational study that at the best should be considered hypothesis generating.

Limitations {#s5}
===========

The clear-cut change in choice of device (primarily IABP from 2010 to 2012, and primarily Impella CP from 2013 to 2017) caused no overlap in time when the two devices were at disposal simultaneously, and given the striking difference in the patient population receiving MCS across the two time periods, we compared early use of IABP and early use of Impella CP to their nearest neighbour control within their respective time periods, instead of comparing early IABP to early Impella CP. In the absence of randomised controlled trials, the propensity score is a method to obtain balance between groups in the search for causal inference and is defined as the probability of receiving treatment given the observed baseline covariates.[@R22] One-to-one nearest-neighbour matching is superior to the classic regression analysis in reducing bias, especially if covariates are poorly balanced between groups.[@R23] Despite propensity matching, the present study carries the risk of confounding by indication, selection bias and bias due to unmatched and unobserved covariates. We chose to exclude patients dying in the catheterisation laboratory before receiving intensive care treatment, which may have underestimated the effect of MCS. However, matched controls in such a setting would have included patients where MCS was abandoned due to futility, which would have led to an overestimation of the MCS effect. We speculate that additional selection bias might have occurred in the early-IABP group, given the lower rate of in-hospital deaths due to multiorgan failure since the IABP does not improve end-organ perfusion or risk of multiorgan dysfunction as demonstrated in an experimental porcine model of moderate acute heart failure and IABP-SHOCK I and II trials.[@R3] The possibility of additional selection bias in the early-Impella CP versus matched control group cannot be excluded as well. Overmatching is a potential limitation as we cannot exclude the possibility of assessment of LVEF/measurement of arterial lactate and creatinine having occurred after initiation of early IABP/Impella CP in some cases. The probability of undermatching is less likely as matching variable strata were narrow and no residual confounding was observed of the continuous variables within their respective strata. Additional overestimation and underestimation of treatment effects could also have occurred, and the influence of a learning curve with the use of Impella CP cannot be excluded. The number of patients who received an early device was limited, and this study does not replace the need for a randomised controlled trial. We do, however, find it encouraging that 30-day mortality improved with early-Impella CP versus matched control group, and not with early-IABP versus matched control group, using the same matching procedure.

Conclusion {#s6}
==========

In this historical follow-up study of patients with AMICS undergoing PCI within 24 hours of symptom onset in southeastern Denmark, the use of MCS decreased by 50% and a shift from IABP to mostly Impella CP occurred following the IABP-SHOCK II trial. Patients receiving MCS after 2012 were younger and presented with more compromised haemodynamics compared with patients receiving MCS prior to 2012. When compared with their respective temporal matched control group, early application of Impella CP was associated with improved survival, while early application of IABP was not.
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